Stanford Cancer Institute
Translating Stanford discoveries into individualized cancer care
The Future of Cancer
The SCI is focused on pushing the limits of what we can do and what we know. The only way to really advance our knowledge is to push forward in laboratories, keep thinking about novel approaches, novel mechanisms. We cannot stand still!
National Cancer Institute Designation
The Stanford Cancer Institute has been designated a Comprehensive Cancer Center by the National Cancer Institute, a part of the National Institutes of Health and the world’s leading cancer research organization.
Designation as a Comprehensive Cancer Center signifies that the Stanford Cancer Institute maintains the highest level of scientific rigor, institutional support and coordination for the complete range of cancer-related research, including basic, translational, clinical and population-based science. The designation is recognition of the institute’s robust and integrated programs encompassing laboratory research, clinical care and community outreach and education.
The Institute’s mission is to support and coordinate the wide range of cancer-related activities — in basic, translational, clinical and population-based science — occurring at Stanford University, Stanford Health Care and Lucile Packard Children’s Hospital Stanford. Its over 450 members include scientists and physicians from a wide range of disciplines, all collaborating to translate research advances into improved cancer treatments.
The new issue of Stanford Medicine magazine features articles about the molecules that make us who we are and how understanding them can lead to medical discoveries and innovations.
Prostate radiation only slightly increases the risk of developing another cancer, Stanford researchers find
Receiving radiation for prostate cancer increases the risk of other cancers very slightly, Stanford Medicine researchers find, allowing providers to better inform patients weighing treatment options.
Stanford Medicine researchers have created a molecule that blocks an enzyme thought to be instrumental in causing colon cancer relapse or chemotherapy resistance.
Cancer Clinical Trials
Stanford Cancer Institute offers leading edge research and compassionate care with over 250 actively recruiting clinical trials, investigating a broad spectrum of new diagnostic, prevention and treatment strategies.